Sara Campos1, Francisco Portela, Paula Sousa, Carlos Sofia. 1. aDepartment of Gastroenterology, Centro Hospitalar e Universitário de Coimbra, Coimbra bDepartment of Gastroenterology, Hospital de São Teotónio, Viseu, Portugal.
Abstract
BACKGROUND: Combination therapy, with anti-tumor necrosis factor-α agents and immunomodulators, is the most effective option to induce and maintain remission in inflammatory bowel disease (IBD). Infliximab, with its administration features, determines particular conditions of adherence; the same is not possible with thiopurines. Nevertheless, research on adherence to these treatments is scarce. Nonadherence worsens the prognosis of IBD. AIM: (a) Assess adherence to immunomodulators and (b) determine therapeutic nonadherence predictors. PATIENTS AND METHODS: We included all IBD outpatients consecutively evaluated over a 6-month period in our center. Participants completed a study-specific questionnaire on IBD, IBD therapeutic adherence (Morisky Medication Adherence Scale-8-item), Therapeutics Complexity questionnaire, Beliefs about Medication questionnaire, and Hospital Anxiety and Depression Scale. RESULTS: A total of 112 patients under azathioprine were considered; 49.1% were also under anti-tumor necrosis factor-α. Self-assessed questionnaire showed that 70.5% were adherent to immunosuppression. Similar adherence was found with and without infliximab (68.4%-monotherapy vs. 72.7%-combination therapy; P=0.61). Nonintentional nonadherence was documented in 57.6%; 42.4% reported voluntary nonadherence. Nonadherence was higher in male patients [odds ratio (OR): 3.79; 95% confidence interval (CI): 1.2-11.95; P=0.023], younger patients (OR: 0.93; 95% CI: 0.87-0.98; P=0.01), nonsmokers (OR: 4.90; 95% CI: 1.22-19.73; P=0.025), and those who had depression (OR: 2.22; 95% CI: 1.36-3.62; P=0.001). Most of the IBD patients believed in the necessity of maintaining immunosuppression (86.7%), but 36.6% reported concerns about drugs. CONCLUSION: Nonadherence to thiopurines plays a significant role in IBD. Nonetheless, it does not increase with association with biological agents. Involuntary nonadherence is higher. Male sex, younger age, nonsmoker, and presence of depression were independent predictors of nonadherence to immunomodulators. More than one-third of IBD patients had concerns about drugs. Optimizing the discussion on patients' concerns to overcome perceptual barriers related to drugs may obviate the negative course of IBD related to nonadherence.
BACKGROUND: Combination therapy, with anti-tumor necrosis factor-α agents and immunomodulators, is the most effective option to induce and maintain remission in inflammatory bowel disease (IBD). Infliximab, with its administration features, determines particular conditions of adherence; the same is not possible with thiopurines. Nevertheless, research on adherence to these treatments is scarce. Nonadherence worsens the prognosis of IBD. AIM: (a) Assess adherence to immunomodulators and (b) determine therapeutic nonadherence predictors. PATIENTS AND METHODS: We included all IBD outpatients consecutively evaluated over a 6-month period in our center. Participants completed a study-specific questionnaire on IBD, IBD therapeutic adherence (Morisky Medication Adherence Scale-8-item), Therapeutics Complexity questionnaire, Beliefs about Medication questionnaire, and Hospital Anxiety and Depression Scale. RESULTS: A total of 112 patients under azathioprine were considered; 49.1% were also under anti-tumor necrosis factor-α. Self-assessed questionnaire showed that 70.5% were adherent to immunosuppression. Similar adherence was found with and without infliximab (68.4%-monotherapy vs. 72.7%-combination therapy; P=0.61). Nonintentional nonadherence was documented in 57.6%; 42.4% reported voluntary nonadherence. Nonadherence was higher in male patients [odds ratio (OR): 3.79; 95% confidence interval (CI): 1.2-11.95; P=0.023], younger patients (OR: 0.93; 95% CI: 0.87-0.98; P=0.01), nonsmokers (OR: 4.90; 95% CI: 1.22-19.73; P=0.025), and those who had depression (OR: 2.22; 95% CI: 1.36-3.62; P=0.001). Most of the IBD patients believed in the necessity of maintaining immunosuppression (86.7%), but 36.6% reported concerns about drugs. CONCLUSION: Nonadherence to thiopurines plays a significant role in IBD. Nonetheless, it does not increase with association with biological agents. Involuntary nonadherence is higher. Male sex, younger age, nonsmoker, and presence of depression were independent predictors of nonadherence to immunomodulators. More than one-third of IBD patients had concerns about drugs. Optimizing the discussion on patients' concerns to overcome perceptual barriers related to drugs may obviate the negative course of IBD related to nonadherence.
Authors: James W Varni; Robert J Shulman; Mariella M Self; Shehzad A Saeed; George M Zacur; Ashish S Patel; Samuel Nurko; Deborah A Neigut; James P Franciosi; Miguel Saps; Jolanda M Denham; Chelsea Vaughan Dark; Cristiane B Bendo; John F Pohl Journal: Qual Life Res Date: 2017-09-08 Impact factor: 4.147
Authors: Mark M T J Broekman; Marieke J H Coenen; Geert J Wanten; Corine J van Marrewijk; Wietske Kievit; Olaf H Klungel; André L M Verbeek; Dennis R Wong; Piet M Hooymans; Henk-Jan Guchelaar; Hans Scheffer; Luc J J Derijks; Marcel L Bouvy; Dirk J de Jong Journal: Eur J Gastroenterol Hepatol Date: 2018-02 Impact factor: 2.566
Authors: James K Stone; Leigh Anne Shafer; Lesley A Graff; Lisa Lix; Kelcie Witges; Laura E Targownik; Clove Haviva; Kathryn Sexton; Charles N Bernstein Journal: Inflamm Bowel Dis Date: 2021-02-16 Impact factor: 5.325
Authors: Juan Lasa; Gustavo Correa; Claudia Fuxman; Laura Garbi; Maria Eugenia Linares; Pablo Lubrano; Astrid Rausch; Martin Toro; Martin Yantorno; Ignacio Zubiaurre; Laurent Peyrin-Biroulet; Pablo Olivera Journal: Gastroenterol Res Pract Date: 2020-01-17 Impact factor: 2.260